Skip to navigation Skip to content



Company Announces First Results from Trial of Masitinib in Progressive MS

February 24, 2020

AB Science announced in a press release initial, positive results from a later-stage clinical trial of oral masitinib involving people with primary progressive MS and “non-active” secondary progressive MS
  • The announced results, based on a subgroup of 301 trial participants over 3 years, suggested that masitinib was beneficial in slowing disease progression compared to inactive placebo, as measured by the standard EDSS scale that largely tests walking ability.
  • Masitinib is a “tyrosine kinase inhibitor” that targets biochemical activities in immune cells that are largely involved in the innate immune system, which is thought to be a driving force within the brain and spinal cord in progressive phases of MS.
  • Results from earlier studies suggest masitinib is relatively well tolerated. The most common possible side effects were weakness (asthenia), rash, nausea, fluid retention, and diarrhea.
  • In addition to being tested in progressive MS, masitinib is being tested for a variety of cancers, asthma, and neurodegenerative disorders. No form of this class of drug has been approved for any form of multiple sclerosis.
  • The company plans to release more detailed results at an upcoming medical meeting. The company states that it will use these results to gain advice from drug regulatory agencies to map out what further phase 3 trial or trials will be needed to submit applications for marketing approval for the treatment of progressive MS.
Read More
About the trial on

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.